Lamb, L., Markert, J., Yancey Gillespie, G., Beelen, M., Langford, C., Pereboeva, L., . . . Nabors, L. (2019). ATIM-22. PHASE I TRIAL OF DRUG RESISTANT IMMUNOTHERAPY: A FIRST-IN-CLASS COMBINATION OF MGMT-MODIFIEDγδ T CELLS AND TEMOZOLOMIDE CHEMOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME. Neuro Oncol.

Lamb, Lawrence, James Markert, G. Yancey Gillespie, Melissa Beelen, Catherine Langford, Larisa Pereboeva, Samantha Youngblood, and Louis Nabors. "ATIM-22. PHASE I TRIAL OF DRUG RESISTANT IMMUNOTHERAPY: A FIRST-IN-CLASS COMBINATION OF MGMT-MODIFIEDγδ T CELLS AND TEMOZOLOMIDE CHEMOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME." Neuro Oncol 2019.

Lamb, Lawrence, et al. "ATIM-22. PHASE I TRIAL OF DRUG RESISTANT IMMUNOTHERAPY: A FIRST-IN-CLASS COMBINATION OF MGMT-MODIFIEDγδ T CELLS AND TEMOZOLOMIDE CHEMOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME." Neuro Oncol 2019.